Literature DB >> 24720678

Curing chronic hepatitis C--the arc of a medical triumph.

Raymond T Chung1, Thomas F Baumert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24720678     DOI： 10.1056/NEJMp1400986

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  108 in total

1.  Viral hepatitis: A new HCV cell culture model for the next clinical challenges.

Authors:  Che C Colpitts; Thomas F Baumert
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-06       Impact factor: 46.802

2.  Clinical development of hepatitis C virus host-targeting agents.

Authors:  Mirjam B Zeisel; Thomas F Baumert
Journal:  Lancet       Date:  2017-01-11       Impact factor: 79.321

3.  Short-Term Incidence of Sequelae of HCV Infection Among Medicaid Beneficiaries in Oregon.

Authors:  Kazuaki Jindai; Courtney Crawford; Ann R Thomas
Journal:  Public Health Rep       Date:  2018-12-03       Impact factor: 2.792

4.  New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A.

Authors:  Lucie Fénéant; Julie Potel; Catherine François; Famara Sané; Florian Douam; Sandrine Belouzard; Noémie Calland; Thibaut Vausselin; Yves Rouillé; Véronique Descamps; Thomas F Baumert; Gilles Duverlie; Dimitri Lavillette; Didier Hober; Jean Dubuisson; Czeslaw Wychowski; Laurence Cocquerel
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

5.  Time to update radiological criteria for non-invasive diagnosis of hepatocellular carcinoma.

Authors:  Sanjay Saini; Daniel S Pratt
Journal:  Hepatol Int       Date:  2014-11-02       Impact factor: 6.047

6.  Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability?

Authors:  Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-06

7.  A new HCV mouse model on the block.

Authors:  Rajiv G Tawar; Laurent Mailly; Thomas F Baumert
Journal:  Cell Res       Date:  2014-09-26       Impact factor: 25.617

8.  Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.

Authors:  Rolando Paciello; Richard A Urbanowicz; Gennaro Riccio; Emanuele Sasso; C Patrick McClure; Nicola Zambrano; Jonathan K Ball; Riccardo Cortese; Alfredo Nicosia; Claudia De Lorenzo
Journal:  J Gen Virol       Date:  2015-10-29       Impact factor: 3.891

9.  Molecular classification of hepatocellular carcinoma: potential therapeutic implications.

Authors:  Nicolas Goossens; Xiaochen Sun; Yujin Hoshida
Journal:  Hepat Oncol       Date:  2015

10.  Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.

Authors:  Muriel Lavie; Stéphane Sarrazin; Roland Montserret; Véronique Descamps; Thomas F Baumert; Gilles Duverlie; Karin Séron; François Penin; Jean Dubuisson
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.